Modulation of Biological Responses of Tumor Cells Adhered to Poly(2-methoxyethyl acrylate) with Increasing Cell Viability under Serum-Free Conditions
Source abstract
Abstract
Circulating tumor cells in body fluids are important biomarkers in cancer diagnosis. The culture of tumor cells isolated from body fluids can provide intrinsic information about tumors and can be used to screen for the best anticancer drugs. However, the culture of primary tumor cells has been hindered by their low viability and difficulties in recapitulating the phenotype of primary tumors in in vitro culture. The culture of tumor cells under serum-free conditions is one of the methodologies to maintain the phenotype and genotype of primary tumors. Poly(2-methoxyethyl acrylate) (PMEA)-coated substrates have been investigated to prolong the proliferation of tumor cells under serum-free conditions. In this study, we investigated the detailed behavior and the mechanism of the increase in tumor cell viability after adherence to PMEA substrates. The blebbing formation of tumor cells on PMEA was attributed not to apoptosis but to the low adhesion strength of cells on PMEA. Moreover, blebbing tumor cells showed amoeboid movement and formed clusters with other cells via N-cadherin, leading to an increase in tumor cell viability. Furthermore, the behaviors of tumor cells adhered to PMEA under serum-free conditions were involved in the activation of the PI3K and Rho-associated protein kinase pathways. Thus, we propose that PMEA would be suitable for the development of devices to cultivate primary tumor cells under serum-free conditions for the label-free diagnosis of cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Materials Chemistry and Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
Funding
Japan Society for the Promotion of Science · Fukuoka Public Health Promotion Organization Cancer research Fund
References (60)
Show source-provided references
1. 10.1039/c9tb01490j10.1039/c9tb01490j ↗
2. 10.1038/s41568-019-0180-210.1038/s41568-019-0180-2 ↗
3. 10.1126/science.120354310.1126/science.1203543 ↗
4. 10.1038/nprot.2017.12510.1038/nprot.2017.125 ↗
5. 10.1126/sciadv.160027410.1126/sciadv.1600274 ↗
6. 10.1038/srep1227010.1038/srep12270 ↗
7. 10.1021/acs.analchem.8b0543210.1021/acs.analchem.8b05432 ↗
8. 10.1039/c8cc09108k10.1039/c8cc09108k ↗
9. 10.1016/j.colsurfb.2019.05.06810.1016/j.colsurfb.2019.05.068 ↗
10. 10.1002/adfm.20150242010.1002/adfm.201502420 ↗
11. 10.1021/acsami.9b1031810.1021/acsami.9b10318 ↗
12. 10.1021/ja000774f10.1021/ja000774f ↗
13. 10.1038/pj.2012.22910.1038/pj.2012.229 ↗
14. 10.1246/bcsj.2019027410.1246/bcsj.20190274 ↗
15. 10.1021/acs.macromol.0c0114410.1021/acs.macromol.0c01144 ↗
16. 10.1016/j.colsurfb.2020.11144910.1016/j.colsurfb.2020.111449 ↗
17. 10.1371/journal.pone.013606610.1371/journal.pone.0136066 ↗
18. 10.3390/coatings1104046110.3390/coatings11040461 ↗
19. 10.1021/acsami.5b0521010.1021/acsami.5b05210 ↗
20. 10.1021/acs.biomac.6b0134010.1021/acs.biomac.6b01340 ↗
21. 10.1016/j.colsurfb.2016.05.05710.1016/j.colsurfb.2016.05.057 ↗
22. 10.1039/c6ra15229e10.1039/c6ra15229e ↗
23. 10.1002/ijc.291054011210.1002/ijc.2910540112 ↗
24. Friedrichs K. · Cancer Res. · 1995 · 55 · 901
25. 10.7150/thno.3433710.7150/thno.34337 ↗
26. 10.1126/science.124325910.1126/science.1243259 ↗
27. 10.18632/oncotarget.2307910.18632/oncotarget.23079 ↗
28. 10.3389/fgene.2019.0095810.3389/fgene.2019.00958 ↗
29. 10.18632/oncotarget.390310.18632/oncotarget.3903 ↗
30. 10.21037/tlcr-20-52110.21037/tlcr-20-521 ↗
31. 10.1039/c003509b10.1039/c003509b ↗
32. 10.1016/j.ccr.2006.03.03010.1016/j.ccr.2006.03.030 ↗
33. 10.1021/acsabm.9b0088510.1021/acsabm.9b00885 ↗
34. 10.1016/j.actbio.2021.07.05810.1016/j.actbio.2021.07.058 ↗
35. 10.1038/cddiscovery.2015.6910.1038/cddiscovery.2015.69 ↗
36. 10.1016/j.celrep.2017.08.00610.1016/j.celrep.2017.08.006 ↗
37. 10.1016/j.ceb.2013.05.00510.1016/j.ceb.2013.05.005 ↗
38. 10.1016/j.stem.2010.06.01810.1016/j.stem.2010.06.018 ↗
39. 10.1021/acs.biomac.7b0124710.1021/acs.biomac.7b01247 ↗
40. 10.1038/cr.2011.20210.1038/cr.2011.202 ↗
41. 10.1111/febs.1622010.1111/febs.16220 ↗
42. 10.1021/bi025752f10.1021/bi025752f ↗
43. 10.1242/jcs.113.10.167710.1242/jcs.113.10.1677 ↗
44. 10.1074/jbc.M40531920010.1074/jbc.M405319200 ↗
45. 10.1083/jcb.20060208510.1083/jcb.200602085 ↗
46. 10.1096/fj.14-25019110.1096/fj.14-250191 ↗
47. 10.1016/j.cellsig.2011.10.00510.1016/j.cellsig.2011.10.005 ↗
48. 10.1523/jneurosci.18-10-03659.199810.1523/jneurosci.18-10-03659.1998 ↗
49. 10.1083/jcb.20080208110.1083/jcb.200802081 ↗
50. 10.1038/ncb101910.1038/ncb1019 ↗
51. 10.3390/ijms2204182110.3390/ijms22041821 ↗
52. Hegerfeldt Y. · Cancer Res. · 2002 · 62 · 2125
53. 10.1007/s13277-016-5464-510.1007/s13277-016-5464-5 ↗
54. Li G. · Cancer Res. · 2001 · 61 · 3819
55. 10.1002/neu.2003610.1002/neu.20036 ↗
56. 10.1038/mtm.2015.1410.1038/mtm.2015.14 ↗
57. 10.1023/B:MCBI.0000021373.14288.0010.1023/B:MCBI.0000021373.14288.00 ↗
58. 10.1091/mbc.E05-07-062610.1091/mbc.E05-07-0626 ↗
59. 10.1042/bc2007001110.1042/bc20070011 ↗
60. 10.1016/j.tibs.2021.05.00510.1016/j.tibs.2021.05.005 ↗